Last Price$59.76.8%
Market Cap$3,532.4M
624.1%
Peers median - 14.7%
42.1%
Peers median - (0.9%)
1.6%
Peers median - 8.2%
259.8%
Peers median - (11.1%)
Competing with PTGX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$3,532.4M | 7.4 | $20.7 65.3% overvalued | 98.3% | $434.4M | $182.8M | 624.1% | 42.1% | 99.6% | 259.8% | 1.6% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
Compare PTGX Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Protagonist Therapeutics, Inc.PTGX
7.2x
624.1%
N/A
63.3%
Median Peer Set
4.0x
14.8%
(19.3%)
7.5%
Alnylam Pharmaceuticals, Inc.ALNY
13.0x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
4.5x
18.0%
139.3%
15.0%
BioNTech SEBNTX
2.0x
(77.4%)
(89.7%)
24.4%
Regeneron Pharmaceuticals, Inc.REGN
4.3x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
9.0x
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
10.9x
11.7%
N/A
(4.9%)
Compare PTGX Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Protagonist Therapeutics, Inc. (PTGX) revenue growth compare to peers and the industry?
Protagonist Therapeutics, Inc. (PTGX) revenue growth is 624.1%, compared to the peers' median of 14.7%.
2. How does Protagonist Therapeutics, Inc. (PTGX) Free Cash Flow (FCF) margin compare to peers and the industry?
Protagonist Therapeutics, Inc. (PTGX) FCF margin is 42.1%, compared to the peers' median of (0.9%).
3. How does Protagonist Therapeutics, Inc. (PTGX) Total Debt to Equity ratio compare to peers and the industry?
Protagonist Therapeutics, Inc. (PTGX) Total Debt to Equity ratio is 1.6%, compared to the peers' median of 8.2%.
4. How does Protagonist Therapeutics, Inc. (PTGX) ROIC (Return on Invested Capital) compare to peers and the industry?
Protagonist Therapeutics, Inc. (PTGX) ROIC is 259.8%, compared to the peers' median of (11.1%).